Final thoughts and next steps The market is evolving rapidly
We provide comprehensive support, including nutritional counseling and fitness recommendations, to help you maximize your results and maintain your progress long-term
Researchers have also been investigating how the drug, and other GLP-1 drugs, could be used to treat obesity-related comorbidities, like cardiovascular disease and heart failure
Every lot is independently third-party tested for identity and purity 99% by HPLC and mass spectrometry with a lot-matched Certificate of Analysis available to download on this page
Jiangsu and Kailera report positive topline data for 8mg HRS9531 GLP-1/GIP owenhaskins Jan 20, 2025 3 min read Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have announced positive topline data from the 8mg dose of Hengrui Pharmas Phase 2 clinical trial (HRS9531-203) of HRS9531, a GLP-1/GIP receptor dual agonist, in individuals living with obesity or overweight